CJC-1295 / Ipamorelin

CJC-1295 / Ipamorelin is a research peptide blend combining a growth hormone-releasing hormone (GHRH) analog (CJC-1295) with a selective growth hormone secretagogue receptor (GHSR-1a) agonist (Ipamorelin). In controlled laboratory settings, this dual-peptide formulation has been studied for its interaction with hypothalamic-pituitary axis signaling pathways and pulsatile growth hormone release mechanisms. Due to the complementary receptor activity of both compounds, the blend remains a focus in endocrine and metabolic research frameworks. Preclinical investigations have examined CJC-1295 for its extended GHRH receptor activity and Ipamorelin for its selective ghrelin receptor pathway interaction. Scientific research continues to evaluate their combined receptor-binding dynamics, downstream IGF-1 signaling pathways, and intracellular endocrine modulation mechanisms within experimental models. This research peptide blend is supplied in a 3ML vial and manufactured under strict laboratory-controlled standards. Each batch undergoes analytical verification to confirm molecular identity, purity, and structural integrity. CJC-1295 / Ipamorelin is intended strictly for laboratory research and analytical purposes only and is not for human consumption.